# 26th European Congress on Gynaecological Oncology

congress.esgo.org



### **CONVERGING ROADS IN GYNAECOLOGICAL CANCERS**

### **Instructions for Abstract Authors**

- Abstracts can only be submitted via the online form, abstracts submitted by fax or email will not be accepted.
- Abstracts must be submitted in English, using UK English spelling.
- The presenting author of an accepted abstract must register and attend the congress.
- The number of submissions is limited to 3 per presenting author.
- The number of authors is limited to 20 per abstract.
- Provide a short specific title indicating the scientific content of the abstract.

The <u>background</u> and goals of the study should appear clearly to the reader. The <u>methods</u> need to outline patient group, methods applied, statistical considerations, if applicable. <u>Results</u> must contain data (except for Late Breaking abstracts [LBA]- see below), and the <u>conclusion</u> should be clearly expressed. The following structure will be required:

- Introduction/Background\*
- Methodology
- Results\*
- Conclusion\*
- Disclosures\* (online recording via the submission form)
- \*mandatory fields
- The title may not exceed 30 words. PLEASE DO NOT USE CAPITAL LETTERS.
   The abstract text may not be longer than 300 words (excluding title, authors and disclosures).
- All abbreviations must be defined the first time they appear in the text (but do not define in the title).
- Tables, charts and other graphics (for all in total maximum 1) are permitted and must be in high resolution JPG format.
- Authors should indicate their presentation type preference:
  - Oral presentation preferred
  - Paper poster presentation
  - E-poster only
  - Video presentation
  - Oral presentation in the Young investigator session (only for authors up to 40 years)
  - o Place holder for LBA

The Programme committee reserves the right to decide on the final allocation and presentation method.



## ESGQ2025 Congress FEBRUARY 20-23, 2025 ROME, ITALY

## 26th European Congress on Gynaecological Oncology

congress.esgo.org



### **CONVERGING ROADS IN GYNAECOLOGICAL CANCERS**

- Disclosure of potential conflict of interest (e.g., grant support, consultancy, membership on advisory councils, speaker's bureau) by all authors and source of funding are mandatory. The submitting author is responsible for collecting a Conflict of interest form for all co-authors. All disclosures should be listed within the last 3 years. A COI template is available: <u>ESGO congress COI form</u>
- **Video presentation** (abstract): Please note the abstract shall be accompanied with the video file. The file should be in .mp4 format with max. size of 500MB and maximum 5 minutes long.
- Abstracts submitted via commercial entities will be considered. However, these
  abstracts should report results from collaborative research conducted by
  independent (non-commercial) investigators. Investigators, as contributing authors
  who are employees of commercial entities will only be accepted if independent
  (academic, clinical and/or scientific) investigators are included as authors. The
  presenting author should not be an employee of the company.
- Systematic review/meta-analysis abstracts are acceptable.
- **Trials in progress (TiP)** can be accepted as posters/e-posters but will not be accepted as oral presentations. These should not previously have been presented as TIP at an ESGO congress. TiP abstracts have a separate category/topic.
- **Encore abstracts** (from key data presented at 2024 international meeting as an oral presentation) can be accepted only if have not been published; with modification and new data, if possible. In case of a conflict of interest, please do not hesitate to contact us for clarification.
- If several abstracts are based on similar analyses of the same database and one of them is selected for oral presentation, the authors might be asked to combine some/all data into one presentation.
- **Case reports** for single cases will not be accepted unless they contain substantial translational work.
- Late Breaking Abstracts (LBA) are generally reserved for <u>newly emerging</u> data that is not available at the time of abstract submission. These could be for initial presentation of results, or significant secondary endpoint analyses. A placeholder LBA <u>must be</u> submitted containing the preliminary title, background, methods and type of results that will be presented. LBA will generally not be accepted at a later date unless a shell abstract has been submitted.

